Sector News

Coloplast picks up voice box maker Atos Medical in €2B deal

November 14, 2021
Life sciences

Danish medtech Coloplast has agreed to acquire voice box maker Atos Medical for 2.15 billion euros, or about $2.49 billion.

That deal represents a healthy return for Atos’ private equity owner, Paris-based PAI Partners, which bought the Swedish company back in 2016 for about 850 million euros. Coloplast describes Atos as an international market leader in the field of laryngectomy and a potential route to a new chronic care business.

Founded in 1986, Atos has been producing prosthetic voice boxes for over 30 years, designed for patients who have had their larynx surgically removed due to cancer or other conditions.

The company introduced an updated version of its Provox device in 2014, which helped users to speak hands-free. Since then, it has launched a smartphone app for voice rehabilitation exercises as well as devices designed for pediatric cases.

After the closure of the deal, which is slated for early 2022, Coloplast plans to run Atos as a separate strategic unit and brand; however, the company will operate on a shared business infrastructure that also supports Coloplast’s offerings in urology, continence and wound care, according to a statement.

Atos recently completed an acquisition of its own—nabbing three companies in one—to diversify into products for patients who have received a tube placed in their windpipe.

A deal was finalized last month for the German tracheostomy group TRACOE medical, which also oversees the Netherlands-based airway management developer MC Europe, and Kapitex, a U.K. manufacturer and distributor of medical devices for people with trouble swallowing.

“I am convinced that combining our companies will strengthen our ability to fast track the journey towards becoming a full range global player in the tracheostomy segment through a combined hospital and direct-to-consumer model and with a strong production footprint in Sweden and Germany,” Atos CEO Britt Meelby Jensen said in a statement when the deals closed Oct. 1.

The sale to Coloplast follows a report from Reuters this past summer that Atos Medical was gearing up to go public, potentially aiming for a 2 billion euro valuation.

“It has been very rewarding to be able to support Atos Medical’s growth in the last few years, with the company more than doubling in size and transforming into a true direct-to-consumer medtech company,” said Andreas Kumeth, partner at PAI. “We are also proud to have played a role in helping Atos Medical establish further specialities and become a more diversified ENT specialist.”

by Conor Hale

Source: fiercebiotech.com

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach